SCHEMBL5250247

SCHEMBL5250247

FC(F)(F)c1cc(-c2nc3nc4ccccc4nc3[nH]2)cc(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.56
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
HSD17B10 Q99714 2/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
THRB P10828 1/20 0.56
CYP2C9 P11712 1/20 0.56
PKM P14618 1/20 0.56
TSHR P16473 1/20 0.56
STAT6 P42226 1/20 0.56
HTT P42858 1/20 0.56
RAB9A P51151 1/20 0.56
KMT2A Q03164 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HIF1A Q16665 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
NPBWR1 P48145 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14493280 0.81 NPBWR1 (0.46) HPGDKDM4EALDH1A1HSD17B10MEN1
SCHEMBL5249728 0.77 GAA (0.53) HPGDKDM4EALDH1A1HSD17B10MEN1
SCHEMBL24347819 0.77 NPBWR1 (0.61) HPGDKDM4EALDH1A1HSD17B10MEN1
SCHEMBL5252061 0.72 TNKS (0.53) HPGDKDM4EALDH1A1HSD17B10MEN1
SCHEMBL2681339 0.71 CYP1A2 (1.00) HPGDKDM4EALDH1A1HSD17B10MEN1
SCHEMBL30260463 0.71 CYP1A2 (1.00) HPGDKDM4EALDH1A1HSD17B10MEN1
SCHEMBL5943243 0.69 KDR (0.44) HPGDKDM4EALDH1A1NPC1PKM
SCHEMBL5252814 0.69 KDM4E (0.61) HPGDKDM4EALDH1A1HSD17B10MEN1
SCHEMBL5249576 0.68 KDM4E (0.61) HPGDKDM4EALDH1A1MEN1NPC1
SCHEMBL5250588 0.67 GUSB (0.62) ALDH1A1MEN1NPC1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1373270-B1 TRICYCLIC QUINOXALINE DERIVATIVES AS A UV FILTER MERCK PATENT GMBH (DE) 2007-06-06 EP disclosed
EP-1373270-B1 TRICYCLIC QUINOXALINE DERIVATIVES AS A UV FILTER MERCK PATENT GMBH (DE) 2007-06-06 EP disclosed
US-20060222607-A1 Tricyclic quinoxaline and quinoline derivatives as UV filters PFLUCKER FRANK 2006-10-05 US disclosed
US-7101537-B2 Tricyclic quinoxaline and quinoline derivatives as a UV filter MERCK PATENTGESELLSCHAFT (DE) 2006-09-05 US disclosed
US-20040102446-A1 Tricyclic quinoxaline derivatives as a uv filter MERCK PATENT GMBH (DE) 2004-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102446-A1 Tricyclic quinoxaline derivatives as a uv filter CUTA, CYP1B1, TPH1 HPGD 237/4885KDM4E 1646/4885ALDH1A1 289/4885
US-20060222607-A1 Tricyclic quinoxaline and quinoline derivatives as UV filters RECQL, CUTA, NQO2 HPGD 231/4885KDM4E 1602/4885ALDH1A1 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.